Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, gives an overview of the European LeukemiaNet (ELN) recommendations on measurable residual disease (MRD) in acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).